龙源期刊网 http://www.qikan.com.cn
吉西他滨联合替吡法尼治疗胰腺癌的有效性和安全性的meta分析
作者：王灵芝 唐松云 涂剑 谢伟全 来源：《上海医药》2020年第05期
摘 要 目的：评价吉西他滨联合替吡法尼治疗胰腺癌的有效性和安全性。方法：通过计算机检索Cochrane Library、PubMed、中国生物医学文献数据库、中国知网和万方等数据库，收集吉西他滨联合替吡法尼治疗胰腺癌的临床随机对照试验（RCT），对吉西他滨联合替吡法尼治疗胰腺癌的有效性和安全性进行meta分析。结果：最终纳入2项RCT，共计932例患者。meta分析结果显示：吉西他滨联合替吡法尼治疗胰腺癌，对延长胰腺癌患者生存期无明显优势（P>0.05），且会提高患者中性粒细胞减少和周围神经病变的发生率，但可以降低患者呼吸困难的发生率。结论：吉西他滨与替吡法尼联合用药与吉西他滨单药治疗胰腺癌相比没有显著的优越性。
关键词 吉西他滨 替吡法尼 胰腺癌 meta分析
中图分类号：R979.19； R735.9 文献标志码：A 文章编号：1006-1533（2020）05-0034-06 Meta-analysis of the efficacy and safety of gemcitaine combined with tipifarnib in the treatment of pancreatic cancer*
WANG Lingzhi1**， TANG Songyun2， TU Jian1，3， XIE Weiquan1，3***
（1. the Cooperative Innovation Center for Molecular Targeting New Drug Study， University of South China， Hu’nan Hengyang 421001， China； 2. Hengyang Central Hospital， Hu’nan Hengyang 421001， China； 3. Institute of Pharmacy & Pharmacology， University of South China， Hu’nan Hengyang 421001， China）
ABSTRACT Objective： To assess the efficacy and safety of gemcitabine plus tipifarnib for the treatment of pancreatic cancer by meta-analysis. Methods： The data from some randomized controlled trials （RCT） of gemcitabine plus teprefini in the treatment of pancreatic cancer were collected by searching for Cochrane Library， PubMed， CBM， CNKI， and Wanfang database and their efficacy and safety were analyzed using RevMan 5.3 software. Results： A total of 2 studies and 932 patients were included. The results of meta-analysis indicated that the combination
chemotherapy of gemcitabine and teprefini in the treatment of pancreatic cancer had no significant advantage in prolonging the survival of patients with pancreatic cancer compared with the single-agent chemotherapy （P>0.05）， and would increase the incidence of neutropenia and peripheral
吉西他滨联合替吡法尼治疗胰腺癌的有效性和安全性的meta分析
